Page 23 - Breakthrough Device News Today

/PRNewswire/ -- On April 27, 2022, GyroStim became the first FDA-cleared device for treating balance disorders to receive FDA designation as a Breakthrough...

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not...

Spectral Announces Second Quarter 2022 Results and Provides Corporate Update - read this article along with other careers information, tips and advice on BioSpace

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing...

/PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life...

/PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life...

/PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today...

Munster, [Germany], July 30 (ANI/PRNewswire): LIMES (Prospective Multi-Center Randomized Controlled Trial to Evaluate the Safety and Efficacy of SiroLIMus Drug-Coated Balloon versus Standard Angioplasty for the Treatment of Infrapopliteal Occlusions in Patients with PEripheral Arterial DiSease) has already enrolled 15 patients, which is encouraging as the Company looks to take a leap in the peripheral artery disease (PAD) treatment. Initiated by the University Hospitals Jena and Leipzig in Germa...

Concept Medical Inc., a pioneer in developing drug delivery device platforms for vascular intervention, has announced the initiation of LIMES trial. MÜNSTER, Germany, July 29, 2022 /PRNewswire/

/PRNewswire/ -- LIMES (Prospective Multi-Center Randomized Controlled Trial to Evaluate the Safety and Efficacy of SiroLIMus Drug Coated Balloon versus...